headerseite_erythrozyten
headerseite_befruchtung
headerseite_wabe
headerseite_nerv3
headerseite_nerv4
headerseite_binaer
headerseite_nerv1b
headerseite_nerv1
headerseite_bakterien
headerseite_chip
headerseite_neurotrans
headerseite_nerv2
headerseite_dna

EMA logoFor the development of new medicines, especially those targeting unmet medical needs, it is vital that communication between developers is as efficient as possible. In order to improve interaction between medical developers, the European Medicines Agency (EMA) has launched a new scheme called PRIME.

PRIME is a voluntary scheme, which is based on enhanced interaction and early dialogue with developers of promising medicines. Ultimately, the goal is to optimise development plans and speed up evaluation so that novel medicines can reach patients more easily. Through PRIME, EMA offers early and proactive support to medicine developers to optimise the generation of robust data on medicine’s benefits and risks. This will also enable accelerated assessment of medicines’ applications.

Thus, patients benefit as early as possible from therapies that may significantly improve their quality of life.

For more information, please visit the website or have a look at the press conference: https://youtu.be/q9LOVKeYvbw